Search
To compare the developmental and behavioral outcomes of children experiencing an initial vaccine-proximate (VP) febrile seizure (FS) to those having a non-VP-FS (NVP-FS) and controls who have not had a seizure.
A multi-country randomized, placebo-controlled trial of the safety, immunogenicity and efficacy of respiratory syncytial virus (RSV) F-protein nanoparticle vaccine was undertaken in 4,636 pregnant women and their infants. RSV F-protein vaccine was safe and immunogenic in the pregnant women inducing anti-F IgG, palivizumab-competing antibodies and RSV neutralizing antibodies that were transferred to the fetus.
Respiratory syncytial virus (RSV) is a global cause of severe respiratory morbidity and mortality in infants. While preventive and therapeutic interventions are being developed, including antivirals, vaccines and monoclonal antibodies, little is known about the global molecular epidemiology of RSV. INFORM is a prospective, multicenter, global clinical study performed by ReSViNET to investigate the worldwide molecular diversity of RSV isolates collected from children less than 5 years of age.
The Wesfarmers Centre of Vaccines & Infectious Diseases brings together a number of independent researchers and research teams with a common aim; to find and deliver new and improved solutions to prevent and treat serious infections experienced by children or adolescents.
At the Wesfarmers Centre, we undertake research in five key areas of infections and immunisation to assist in children's health.
Researchers from The Kids Research Institute Australia would like to understand more about respiratory syncytial virus (RSV) and how we can provide the best protection for kids.
Review the hospital-based research that the Wesfamers Centre of Vaccines & Infectious Diseases conducts.
We are evaluating new vaccines for a range of diseases including influenza, pneumococcal, meningococcal and common infections such as otitis media (glue ear).
Vaccine Trials Group with Sir Charles Gairdner Hospital is conducting a trial of a vaccine against Clostridium difficile infection (CDI) in at-risk individuals.
The study aims to determine whether an RSV vaccine given to pregnant women during the third trimester can protect newborn babies from RSV infections.